

Remarks

In the Office Action, Claims 1, 2, 4-15, 18-23 26 and 27 are pending and subject to rejection and/or objection. As described below, the claims have been amended to remove the bases for rejection and/or objection to put them in condition for allowance. No new subject matter has been added.

Claims 22 and 23 are objected to because the definitions rely on definitions of variables set forth in Claim 1. Claims 21-23 have been amended to provide complete definitions of the variables which conform to the definitions of Claim 1, as amended.

Claim 1, and a number of claims which depend from it, are rejected under Section 103(a) over the cited Mashkovsky references; and Claim 22 is rejected under Section 102 over one of those references. To eliminate the bases for rejection, the value of R¹ as piperidin-1-yl has been deleted from Claim 1 (providing a claim of the same scope as the prior, allowable Claim 2) and the remaining claims and definitions have been conformed. As a result Claim 2 is canceled and the dependency of Claim 4 is revised.

The Examiner is requested to reconsider the claims in view of the amendments provided and to find the claims allowable. It is believed that no fee is required for this response; however, the Commissioner hereby is authorized to charge any requisite fee for the response to Deposit Account No. 05-0840. The Examiner is encouraged to telephone the undersigned if it is useful to expedite any aspect of the prosecution.

Respectfully submitted,

/Thomas E. Jackson/

Thomas E. Jackson
Patent Attorney
Registration No. 33064
Phone: 317/277-3735

Eli Lilly and Company
Patent Division/
P.O. Box 6288
Indianapolis, Indiana 46206-6288

6 June 2008